# Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis

> **NCT00970346** · PHASE1 · COMPLETED · sponsor: **AlgiPharma AS** · enrollment: 26 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** OligoG CF-5/20

## Key facts

- **NCT ID:** NCT00970346
- **Lead sponsor:** AlgiPharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-10
- **Final completion:** 2009-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2016-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970346, "Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00970346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*